Chemotherapy-Induced Anemia

Data: Aranesp dosed every 2 weeks is comparable to Epoetin alfa dosed weekly

Published in Drug Week, June 24th, 2005

Amgen, Inc., (AMGN) announced that final results of a phase III, randomized, head-to-head study demonstrated that 200 mcg of Aranesp (darbepoetin alfa) administered every 2 weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.

The data were presented at the 41st annual meeting of the American Society of Clinical Oncology (ASCO) (Abstract #8125).

"This is the largest, randomized, head-to-head comparison of darbepoetin alfa dosed every 2 weeks to Epoetin alfa dosed weekly, as they are most often used in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry